Search Clinical Trials
Sponsor Condition of Interest |
---|
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously...
Gilead Sciences
Triple Negative Breast Cancer
PD-L1 Negative
The primary objective of this study is to compare the progression-free survival (PFS)
between sacituzumab govitecan-hziy (SG) versus treatment of physician's choice (TPC) in
participants with previously untreated, locally advanced, inoperable or metastatic
triple-negative breast cancer whose tumors... expand
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of physician's choice (TPC) in participants with previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do not express programmed cell death ligand 1 (PD-L1) or in participants previously treated with anti-programmed cell death (ligand or protein) 1 (Anti-PD-(L)1) Agents in the early setting whose tumors do express PD-L1. Type: Interventional Start Date: Jul 2022 |
The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease
Massachusetts General Hospital
NAFLD
Nonalcoholic Fatty Liver
NASH - Nonalcoholic Steatohepatitis
Nonalcoholic fatty liver disease (NAFLD), fatty infiltration of the liver in the absence
of alcohol use, is an increasingly recognized complication of obesity, with prevalence
estimates of about 30% of individuals in the United States. A subset of these will
develop progressive disease in the form... expand
Nonalcoholic fatty liver disease (NAFLD), fatty infiltration of the liver in the absence of alcohol use, is an increasingly recognized complication of obesity, with prevalence estimates of about 30% of individuals in the United States. A subset of these will develop progressive disease in the form of nonalcoholic steatohepatitis (NASH), which can progress to cirrhosis and liver failure. The investigators hypothesize that LUM-201 (Ibutamoren mesylate) will decrease intrahepatic lipid accumulation as quantified by proton magnetic resonance spectroscopy (1H-MRS). Type: Interventional Start Date: Aug 2022 |
Psychophysical and Neural Mechanisms Contributing to Chronic Post-Surgical Pain in Adolescents and Adults
Massachusetts General Hospital
Chronic Post-surgical Pain
The current project will (1) enhance our understanding of the neurobiology of chronic
post-surgical pain (CPSP); (2) provide a metric to follow patients with CPSP in the
clinic; (3) provide a metric for those who will chronify; and (4) understand the
age-related differences in CPSP. Ultimately, an... expand
The current project will (1) enhance our understanding of the neurobiology of chronic post-surgical pain (CPSP); (2) provide a metric to follow patients with CPSP in the clinic; (3) provide a metric for those who will chronify; and (4) understand the age-related differences in CPSP. Ultimately, an improved comprehension of mechanisms linked to CPSP will provide finer tools for optimizing the selection of treatments for individual patients. Moreover, data that demonstrates the underlying pathobiological pain mechanism(s) active in CPSP, particularly those non-responsive to current therapies, may be used to validate novel strategies both pharmacological and non-pharmacological. Type: Interventional Start Date: Apr 2022 |
A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants...
Pfizer
Breast Cancer
Solid Tumors
The purpose of this clinical trial is to learn about the safety and effects of the study
medicine (called PF-07220060 and PF-07104091) in people with breast cancer. This clinical
study consists of 2 parts (part 1 and part 2). In part 1, we are seeking participants
who:
- Have been diagnosed... expand
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07220060 and PF-07104091) in people with breast cancer. This clinical study consists of 2 parts (part 1 and part 2). In part 1, we are seeking participants who: - Have been diagnosed with Breast Cancer (BC) of either types: - Have HR+, HER2- BC - Refractory HR-positive/HER2-positive BC - Have other solid tumors other than BC In part 2, we are seeking participants who: -Have HR-positive/HER2-negative BC Part 1 will include increasing doses of PF-07220060 with PF-07104091. In part 2, participants will take 1 of 2 study medicine combinations. This will help us decide the highest amount of study medicines that can be safety given to people. All participants in this study will receive PF-07220060 with PF-07104091 by mouth. We will compare participant experiences to help us determine if PF-07220060 with PF-07104091 is safe and effective. Participants will take part in this study for about 2 years. During this time, they will receive the study medicine, an x-ray imaging, and will be observed for safety and effects of the study medicines. Type: Interventional Start Date: Mar 2022 |
Zenith® Fenestrated+ Clinical Study
Cook Research Incorporated
Aortic Aneurysm, Abdominal
Juxtarenal Aortic Aneurysm
Extent IV Thoracoabdominal
Pararenal Aneurysm
The Zenith® Fenestrated+ Endovascular Graft Clinical Study will assess the safety and
effectiveness of the Zenith® Fenestrated+ Endovascular Graft (ZFEN+) in combination with
the BeGraft Balloon-Expandable FEVAR Bridging Stent Graft System (BeGraft) and Unibody2
for the treatment of patients with... expand
The Zenith® Fenestrated+ Endovascular Graft Clinical Study will assess the safety and effectiveness of the Zenith® Fenestrated+ Endovascular Graft (ZFEN+) in combination with the BeGraft Balloon-Expandable FEVAR Bridging Stent Graft System (BeGraft) and Unibody2 for the treatment of patients with aortic aneurysms involving one or more of the major visceral arteries. Type: Interventional Start Date: Dec 2023 |
Tolerability and Feasibility Pilot Clinical Study of a Large-Diameter Nerve Cap for Protecting and Preserving...
Axogen Corporation
Symptomatic Neuroma
Amputation
Chronic Nerve Pain
This pilot study evaluates the tolerability and feasibility of the Axoguard
Large-Diameter Nerve Cap (sizes 5-7 mm) for protecting and preserving terminated nerve
endings after limb trauma or amputation when immediate attention to the nerve injuries is
not possible. expand
This pilot study evaluates the tolerability and feasibility of the Axoguard Large-Diameter Nerve Cap (sizes 5-7 mm) for protecting and preserving terminated nerve endings after limb trauma or amputation when immediate attention to the nerve injuries is not possible. Type: Interventional Start Date: Mar 2022 |
A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors
Novartis Pharmaceuticals
Mesothelioma
The purpose of this study is to characterize the safety and tolerability of IAG933 in
patients with mesothelioma, NF2/LATS1/LATS2 mutated tumors and tumors with functional
YAP/TAZ fusions and to identify the maximum tolerated dose and/or recommended dose. expand
The purpose of this study is to characterize the safety and tolerability of IAG933 in patients with mesothelioma, NF2/LATS1/LATS2 mutated tumors and tumors with functional YAP/TAZ fusions and to identify the maximum tolerated dose and/or recommended dose. Type: Interventional Start Date: Oct 2021 |
Testing Tumor Tissue and Blood to Help Select Personalized Treatments for Patients With Suspected Lung...
Lung Cancer Mutation Consortium
NSCLC
This collaborative screening protocol, developed by the Lung Cancer Mutation Consortium
(LCMC) and supported by the Thoracic Surgery Oncology Group (TSOG), is designed to
determine the feasibility of comprehensive molecular profiling to detect actionable
oncogenic drivers in patients with suspected... expand
This collaborative screening protocol, developed by the Lung Cancer Mutation Consortium (LCMC) and supported by the Thoracic Surgery Oncology Group (TSOG), is designed to determine the feasibility of comprehensive molecular profiling to detect actionable oncogenic drivers in patients with suspected early stage lung cancers scheduled to undergo biopsies to establish the diagnosis of lung cancer. The primary purpose of this testing is to determine the presence of 12 oncogenic drivers (mutations in EGFR, BRAFV600E , MET exon 14, KRAS G12C and HER2, rearrangements in ALK, RET, NTRK, EGFR exon 20 insertion and ROS1, and amplification of MET and HER2) that can serve as targets making patients eligible for upcoming targeted neoadjuvant therapy trials. The ultimate goal is to use this information from the screening process to select the optimal neoadjuvant therapy and wherever possible enroll patients onto separate neoadjuvant therapy trials with genomically matched treatments or other appropriate trials if no actionable driver mutation is detected. Thoracic Surgery Oncology Group (TSOG) is a network of surgeons within North American Thoracic Surgery Academic Centers aligned with the goal of enhancing patient care through administration of multi-site trials focused on recent advances in lung cancer. TSOG has aligned with the LCMC4 sites to enroll the LCRF-LEADER screening trial. TSOG's involvement will be essential in trial enrollment and ultimate interpretation of the multimodal clinical and translational data collected as part of this study. We estimate we will detect an actionable oncogenic driver in 33% of cases. The remaining 66% of patients will represent a cohort identified by their care teams as candidates for other potential neoadjuvant therapies which may include checkpoint inhibitors such as atezolizumab, durvalumab, nivolumab, and pembrolizumab or other novel agents. The targeted therapy treatment trials will be conducted independently of the LCRF-LEADER screening trial, evaluating for efficacy. If none of the 10 oncogenic drivers are detected, the patient will be offered participation in any clinical trial of neoadjuvant therapy available at their treating institution or standard of care therapy. For patients not enrolled on a targeted treatment trial, circulating tumor DNA in blood (ctDNA) will be collected at 3 time points: before neoadjuvant treatment, after neoadjuvant treatment but before surgery, and after surgery. This initiative will be correlated with various clinical outcomes. Prespecified clinical data will be collected for correlation with these circulating biomarkers. Type: Observational Start Date: Jun 2022 |
Assessment of Safety and Effectiveness of NovoSorb® BTM in Severe Burns
PolyNovo Biomaterials Pty Ltd.
Burns
This is a multi-center, pivotal study to assess the safety and effectiveness of a new
method of treating severe burns using NovoSorb® Biodegradable Temporizing Matrix (BTM). expand
This is a multi-center, pivotal study to assess the safety and effectiveness of a new method of treating severe burns using NovoSorb® Biodegradable Temporizing Matrix (BTM). Type: Interventional Start Date: Sep 2021 |
Vaginal Microbiota Transplant
Douglas Kwon
Recurrent Bacterial Vaginosis
This is a randomized trial of vaginal microbiome transplant vs. saline placebo to restore
a Lactobacillus dominant vaginal microbial community in women with recurrent bacterial
vaginosis. expand
This is a randomized trial of vaginal microbiome transplant vs. saline placebo to restore a Lactobacillus dominant vaginal microbial community in women with recurrent bacterial vaginosis. Type: Interventional Start Date: Apr 2021 |
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma,...
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm
Malignant Solid Neoplasm
Recurrent Ependymoma
Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Recurrent Hepatoblastoma
This phase II Pediatric MATCH treatment trial studies how well ensartinib works in
treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with
ALK or ROS1 genomic alterations that have come back (recurrent) or does not respond to
treatment (refractory) and may have spread... expand
This phase II Pediatric MATCH treatment trial studies how well ensartinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with ALK or ROS1 genomic alterations that have come back (recurrent) or does not respond to treatment (refractory) and may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Ensartinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Type: Interventional Start Date: Apr 2018 |
Radiation Therapy With Protons or Photons in Treating Patients With Liver Cancer
NRG Oncology
Unrectable or Locally Recurrent Hepatocellular Carcinoma
This phase III trial studies how well radiation therapy with protons works compared with
photons in treating patients with liver cancer. Radiation therapy, such as photon
therapy, uses high energy x-rays to send the radiation inside the body to the tumor while
proton therapy uses a beam of proton... expand
This phase III trial studies how well radiation therapy with protons works compared with photons in treating patients with liver cancer. Radiation therapy, such as photon therapy, uses high energy x-rays to send the radiation inside the body to the tumor while proton therapy uses a beam of proton particles. Proton therapy can stop shortly after penetrating through the tumor and may cause less damage to the surrounding healthy organs and result in better survival in patients with liver cancer. Type: Interventional Start Date: Jan 2018 |
Computerized Registry of Patients With Venous Thromboembolism (RIETE)
Manuel Monreal
Venous Thromboembolism
The Computerized Registry of Patients with Venous Thromboembolism (RIETE) is a
multidisciplinary Project initiated in march 2001 and consisting in obtaining an
extensive data registry of consecutive patients with venous thromboembolism.
The main objective is to provide information on the Internet... expand
The Computerized Registry of Patients with Venous Thromboembolism (RIETE) is a multidisciplinary Project initiated in march 2001 and consisting in obtaining an extensive data registry of consecutive patients with venous thromboembolism. The main objective is to provide information on the Internet to help physicians to improve their knowledge on the natural history of thromboembolic disease, particularly in those subgroups of patients who are usually not recruited in randomized clinical trials (pregnant women, elderly patients, disseminated cancer, severe renal insufficiency, patients with contraindications to anticoagulation therapy, extreme body weight, etc), with the purpose of decreasing mortality, frequency of thromboembolic recurrences as well as bleeding complications and arterial events. As an additional objective RIETE is also aimed to create predictive scores that help physicians to better identify patients with high risk of presenting some of these complications. The primary parameters recorded by the registry comprise details of each patient's clinical status, including any coexisting or underlying conditions, and the type, dose, duration and outcome (during the first 3 months of therapy) of antithrombotic treatment. Study endpoints are clinically recognized (and objectively confirmed) recurrences of VTE, major and minor bleeding complications, and death. Type: Observational [Patient Registry] Start Date: Mar 2001 |
Biliary Atresia Research Network Northeast
Yale University
Biliary Atresia
This is a multi-center retrospective chart review to compile a data repository of the
management and outcomes of children with biliary atresia. Overall, investigators aim to
evaluate which specific factors contribute to improved patient outcomes, to help guide
potential improvements in patient care... expand
This is a multi-center retrospective chart review to compile a data repository of the management and outcomes of children with biliary atresia. Overall, investigators aim to evaluate which specific factors contribute to improved patient outcomes, to help guide potential improvements in patient care and resource utilization. Type: Observational Start Date: May 2024 |
TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer
Dana-Farber Cancer Institute
Breast Cancer
Early-stage Breast Cancer
High Risk Breast Carcinoma
In this research study, investigators are testing if a dose-increasing strategy for
abemaciclib will have less side effects and be better tolerated than the standard dosage
of abemaciclib for participants with early-stage high-risk hormone receptor positive
breast cancer.
The names of the study... expand
In this research study, investigators are testing if a dose-increasing strategy for abemaciclib will have less side effects and be better tolerated than the standard dosage of abemaciclib for participants with early-stage high-risk hormone receptor positive breast cancer. The names of the study drugs involved in this study are: - Abemaciclib (CDK4 and CDK6 inhibitor) - Tamoxifen (Selective estrogen receptor modulator) - Anastrozole/Letrozole (Non-steroidal aromatase inhibitors) - Exemestane (steroidal aromatase inhibitor) - LHRH (Gonadotropin-releasing hormone agonist, or Luteinizing hormone-releasing hormone agonist) Type: Interventional Start Date: Oct 2023 |
SIRT With Tremelimumab and Durvalumab for Resectable HCC
Jiping Wang, MD, PhD
Resectable Hepatocellular Carcinoma
Hepatocellular Carcinoma
Hepatocellular Cancer
The goal of this research study is to evaluate the safety and tolerability of
tremelimumab and durvalumab with or without Selective Internal Yttrium-90
Radioembolization (SIRT) in participants with resectable hepatocellular carcinoma (HCC)
who will undergo liver surgery.
The names of the interventions... expand
The goal of this research study is to evaluate the safety and tolerability of tremelimumab and durvalumab with or without Selective Internal Yttrium-90 Radioembolization (SIRT) in participants with resectable hepatocellular carcinoma (HCC) who will undergo liver surgery. The names of the interventions involved in this study are: - Durvalumab (a type of immunotherapy) - Tremelimumab (a type of immunotherapy) - Selective Internal Yttrium-90 Radioembolization (SIRT) (a type of radiation microsphere bead) Type: Interventional Start Date: Apr 2023 |
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib...
Sermonix Pharmaceuticals Inc.
Metastatic Breast Cancer
The goal of this clinical trial is to assess the efficacy, safety and tolerability of the
combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for
the treatment of pre- and postmenopausal women and men who have previously received
ribociclib or palbociclib-based treatment... expand
The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who have previously received ribociclib or palbociclib-based treatment and have locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation. The main question the study aims to answer is: • To compare the efficacy of the combination of lasofoxifene and abemaciclib with that of fulvestrant and abemaciclib Participants will receive either receive 5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day or the combination of fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day. Type: Interventional Start Date: Oct 2023 |
PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4...
Prelude Therapeutics
Advanced Solid Tumor
Metastatic Solid Tumor
Non-small Cell Lung Cancers
SMARCA4 Gene Mutation
This is a Phase 1 dose-escalation study of PRT3789, a SMARCA2 degrader, in participants
with advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation
and/or deletion. The purpose of this study is to evaluate the safety, tolerability,
pharmacokinetic (PK), and pharmacodynamic... expand
This is a Phase 1 dose-escalation study of PRT3789, a SMARCA2 degrader, in participants with advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) of PRT3789 monotherapy and in combination with docetaxel, describe any dose limiting toxicities (DLTs), define the dosing schedule, and to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) to be used in subsequent development of PRT3789. Type: Interventional Start Date: May 2023 |
Doxycycline for Emphysema in People Living With HIV (The DEPTH Trial)
Weill Medical College of Cornell University
Emphysema
HIV
The purpose of this study is to determine if doxycycline will reduce progression of
emphysema in people living with HIV.
The secondary objectives are to examine the effects of doxycycline on change in quantity
of emphysema, six minute walk distance, patient reported outcomes, ratio of forced
expiratory... expand
The purpose of this study is to determine if doxycycline will reduce progression of emphysema in people living with HIV. The secondary objectives are to examine the effects of doxycycline on change in quantity of emphysema, six minute walk distance, patient reported outcomes, ratio of forced expiratory volume in 1 second and forced vital capacity. Secondary objectives will also describe the safety and tolerability of doxycycline and determine if doxycycline is associated with development of antibiotic-resistant bacterial infections. Type: Interventional Start Date: Aug 2022 |
Mechanistic Study of the Effect of Itepekimab on Airway Inflammation in Patients With COPD
Sanofi
Chronic Obstructive Pulmonary Disease
This study is an exploratory, two-part, 12-week, Phase 2a study to evaluate the mechanism
of action of Itepekimab (anti-IL-33-mAb) and its impact on airway inflammation in former
and current smokers with COPD, aged 40 to 70 years.
This study consists of participants who have been on a standard-of-care... expand
This study is an exploratory, two-part, 12-week, Phase 2a study to evaluate the mechanism of action of Itepekimab (anti-IL-33-mAb) and its impact on airway inflammation in former and current smokers with COPD, aged 40 to 70 years. This study consists of participants who have been on a standard-of-care (SoC) mono (long-acting β2-agonist [LABA]) or long-acting muscarinic antagonist [LAMA]), double (inhaled corticosteroid [ICS] + LABA, LABA + LAMA or ICS + LAMA), or triple (ICS + LABA + LAMA) controller therapy for COPD for at least 3 months prior to Screening (Visit 1) with stable dose and regimen for controller therapy for ≥1 month prior to Screening (Visit 1) and during the screening period. Participants will stay on their established controller medications for COPD throughout the duration of the study, with the exception of systemic corticosteroids and/or antibiotics used for acute exacerbation of COPD (AECOPD). The total study duration for each part (Part A and Part B) is approximately 36 weeks: - 4-week screening period - 12-week treatment period - 20-week followup period Type: Interventional Start Date: May 2022 |
ATEMPT 2.0: Adjuvant T-DM1 vs TH
Dana-Farber Cancer Institute
Breast Cancer
HER2-positive Breast Cancer
This research study is studying how well newly diagnosed breast cancer that has tested
positive for a protein called HER2 responds using one of two different combination of
HER2-directed therapies as a treatment after surgery.
The name of the study drugs involved are:
- Trastuzumab-emtansine... expand
This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combination of HER2-directed therapies as a treatment after surgery. The name of the study drugs involved are: - Trastuzumab-emtansine (T-DM1, Kadcyla) - Trastuzumab SC (Herceptin Hylecta) - Paclitaxel Type: Interventional Start Date: Jun 2021 |
A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide...
Biogen
Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation
The primary objective of this study is to evaluate the efficacy of tofersen in
presymptomatic adult carriers of a superoxide dismutase 1 (SOD1) mutation with elevated
neurofilament (NF). The secondary objectives of this study are to evaluate the safety and
tolerability tofersen and to evaluate the... expand
The primary objective of this study is to evaluate the efficacy of tofersen in presymptomatic adult carriers of a superoxide dismutase 1 (SOD1) mutation with elevated neurofilament (NF). The secondary objectives of this study are to evaluate the safety and tolerability tofersen and to evaluate the effect of tofersen on pharmacodynamics (PD)/treatment response biomarkers when initiated prior to versus at the time of emergence of clinically manifest amyotrophic lateral sclerosis (ALS). Type: Interventional Start Date: May 2021 |
A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes
Vertex Pharmaceuticals Incorporated
Diabetes Mellitus, Type 1
Impaired Hypoglycemic Awareness
Severe Hypoglycemia
This study will evaluate the safety, tolerability and efficacy of VX-880 infusion in
participants with Type 1 diabetes mellitus (T1D) and impaired awareness of hypoglycemia
(IAH) and severe hypoglycemia. expand
This study will evaluate the safety, tolerability and efficacy of VX-880 infusion in participants with Type 1 diabetes mellitus (T1D) and impaired awareness of hypoglycemia (IAH) and severe hypoglycemia. Type: Interventional Start Date: Mar 2021 |
Renal Allograft Tolerance Through Mixed Chimerism - SMC/MGH
Massachusetts General Hospital
Renal Failure
The goal is to investigate the safety of the conditioning regimen, and its ability to
induce donor/recipient lymphohematopoietic chimerism without Chimerism Transition
Syndrome (CTS), which may result in donor-specific unresponsiveness (tolerance) to the
renal allograft in the absence of maintenance... expand
The goal is to investigate the safety of the conditioning regimen, and its ability to induce donor/recipient lymphohematopoietic chimerism without Chimerism Transition Syndrome (CTS), which may result in donor-specific unresponsiveness (tolerance) to the renal allograft in the absence of maintenance immunosuppression. Type: Interventional Start Date: Sep 2021 |
Prospective Screening for Breast Cancer-related Lymphedema
Massachusetts General Hospital
Lymphedema
The primary objectives of this study are twofold: 1) to detect and determine the level of
symptoms, functional disability, and changes in quality of life that breast cancer
patients experience from changes in their arms during and after treatment for breast
cancer by collecting patient reported outcome... expand
The primary objectives of this study are twofold: 1) to detect and determine the level of symptoms, functional disability, and changes in quality of life that breast cancer patients experience from changes in their arms during and after treatment for breast cancer by collecting patient reported outcome measures, objective measurements, and clinical information in a prospectively maintained database and 2) to improve breast cancer-related lymphedema outcomes by early detection using objective measurements and symptoms assessments and assess these outcomes by maintaining the data in a database in order to contribute to the literature. The secondary aim of this study is to assess extracellular fluid content in the upper extremity, breast, and/or trunk of patients treated for breast cancer before, during, and after treatment in order to better understand the role of bioimpedance spectroscopy in lymphedema screening. Type: Observational Start Date: Aug 2009 |
- Previous
- Next